In this journal van de Wal et al. 1 recently reported that an effective reduction of urinary albumin excretion with the angiotensin-converting enzyme (ACE)-inhibitor fosinopril was not related to plasma matrix metalloproteinase-9 (MMP-9) levels. The authors indicated that the Elisa they used for MMP-9 analysis (Amersham, Buckinghamshire, UK), detects both MMP-9, pro-MMP-9 and the proMMP-9/TIMP-1 complex. However, according to the manufacturer (Amersham, Buckinghamshire, England), this Elisa mainly detects enzymatically inactive pro-MMP-9; active MMP-9 enzyme shows only 3% cross-reactivity relative to pro-MMP-9 in this Elisa (Instructions for use, Elisa code RPN 2614, Amersham).
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ACE and MMP-9 are both zinc-dependent endopeptidases and both process angiotensin (Ang) I to form Ang II. 2 Recent studies indicate that ACE-inhibitors can also inhibit MMP-9 enzymatic activity. 2 Whereas the Amersham Elisa used by van de Wal et al. predominantly detects pro-MMP-9 protein levels, even an Elisa that also detects the activated MMP-9 (e.g. the MMP-9 Immunoassay, code DMP900, produced by RnDsystems) might not be able to discriminate between enzymatically active MMP-9 and MMP-9, inactivated by ACE-inhibitor, because these assays detect immunoreactive MMP-9, but do not determine enzymatic activity of this protein. It would be of interest to relate an ACE-inhibitorinduced reduction of albumin excretion to a plasma MMP-9 (enzymatic) activity assay, which is also available through Amersham (product code RPN 2630). 
